Condition: Non Hodgkin Lymphoma · Richter Transformation · Multiple Myeloma · Sponsor: Newave Pharmaceutical Inc
This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up to 100 subjects.
This description comes directly from the study's public registry record.
Anna Chen, MD, PhD · (206) 335-3820 · yu@newavepharma.com
Stephen Anthony, DO · s.anthony@newavepharma.com
Always discuss trial participation with your own doctor first.
| University of Chicago | Chicago, Illinois, United States | Recruiting |
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| University of North Carolina | Chapel Hill, North Carolina, United States | Recruiting |
| Cincinnati Children's Hospital Medical Center | Cincinnati, Ohio, United States | Recruiting |
| University of Cincinnati | Cincinnati, Ohio, United States | Recruiting |
| The Ohio State University | Columbus, Ohio, United States | Recruiting |
| MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| University of Utah | Salt Lake City, Utah, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04771572